The FASTER-BUP Study, Extended-Release Injectable Buprenorphine for the Treatment of Opioid Use Disorder Among Individuals at High Risk of Overdose : Protocol for an Observational Prospective Study
North America is facing an unprecedented public health emergency of opioid-related morbidity and mortality. The mortality benefits of oral medication treatment for opioid use disorder (MOUD), such as methadone or buprenorphine, are well documented. However, barriers to access and long-term engagement have prevented maximizing their benefits. Long-acting injectable buprenorphine formulations were developed to address some of the challenges associated with oral MOUD. The "Pilot study to assess the feasibility, efficacy, and safety of extended-release injectable buprenorphine for the treatment of opioid use disorder among individuals at high risk of overdose" (FASTER-BUP) was developed to explore this treatment option in populations at high risk of overdose in a real-world Canadian setting. FASTER-BUP is a 24-week observational prospective study evaluating the feasibility and clinical utility of extended-release injectable buprenorphine (XR-BUP) for the treatment of opioid use disorder (OUD) among 40 adults at high risk of overdose (ie, lifetime history of overdose or a positive urine drug test (UDT) for fentanyl within 30 days prior to screening) in Vancouver, BC. The primary outcome is retention in treatment and secondary outcomes include: use of unregulated opioids, safety, overdose events, treatment satisfaction, changes in drug-related problems, changes in quality of life, opioid cravings, health service utilization, and criminal activity. FASTER-BUP is the first study to explore XR-BUP among individuals at high risk of overdose in a real-world Canadian setting. This commentary provides a brief narrative about the study thus far and presents insights on key adaptations to the study protocol, including those adopted to mitigate recruitment challenges.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Substance use & addiction journal - 45(2024), 2 vom: 23. März, Seite 176-180 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Langlois, Jenna [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.03.2024 Date Revised 29.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/29767342231222103 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367447762 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367447762 | ||
| 003 | DE-627 | ||
| 005 | 20240331000858.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240123s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/29767342231222103 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1357.xml |
| 035 | |a (DE-627)NLM367447762 | ||
| 035 | |a (NLM)38254287 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Langlois, Jenna |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The FASTER-BUP Study, Extended-Release Injectable Buprenorphine for the Treatment of Opioid Use Disorder Among Individuals at High Risk of Overdose |b Protocol for an Observational Prospective Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2024 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a North America is facing an unprecedented public health emergency of opioid-related morbidity and mortality. The mortality benefits of oral medication treatment for opioid use disorder (MOUD), such as methadone or buprenorphine, are well documented. However, barriers to access and long-term engagement have prevented maximizing their benefits. Long-acting injectable buprenorphine formulations were developed to address some of the challenges associated with oral MOUD. The "Pilot study to assess the feasibility, efficacy, and safety of extended-release injectable buprenorphine for the treatment of opioid use disorder among individuals at high risk of overdose" (FASTER-BUP) was developed to explore this treatment option in populations at high risk of overdose in a real-world Canadian setting. FASTER-BUP is a 24-week observational prospective study evaluating the feasibility and clinical utility of extended-release injectable buprenorphine (XR-BUP) for the treatment of opioid use disorder (OUD) among 40 adults at high risk of overdose (ie, lifetime history of overdose or a positive urine drug test (UDT) for fentanyl within 30 days prior to screening) in Vancouver, BC. The primary outcome is retention in treatment and secondary outcomes include: use of unregulated opioids, safety, overdose events, treatment satisfaction, changes in drug-related problems, changes in quality of life, opioid cravings, health service utilization, and criminal activity. FASTER-BUP is the first study to explore XR-BUP among individuals at high risk of overdose in a real-world Canadian setting. This commentary provides a brief narrative about the study thus far and presents insights on key adaptations to the study protocol, including those adopted to mitigate recruitment challenges | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a extended-release injectable buprenorphine | |
| 650 | 4 | |a observational prospective study | |
| 650 | 4 | |a opioid use disorder | |
| 650 | 4 | |a overdose | |
| 650 | 7 | |a Analgesics, Opioid |2 NLM | |
| 650 | 7 | |a Buprenorphine |2 NLM | |
| 650 | 7 | |a 40D3SCR4GZ |2 NLM | |
| 650 | 7 | |a Naltrexone |2 NLM | |
| 650 | 7 | |a 5S6W795CQM |2 NLM | |
| 650 | 7 | |a Narcotic Antagonists |2 NLM | |
| 700 | 1 | |a Nolan, Seonaid |e verfasserin |4 aut | |
| 700 | 1 | |a Dickhout, Piper |e verfasserin |4 aut | |
| 700 | 1 | |a Cui, Zishan |e verfasserin |4 aut | |
| 700 | 1 | |a Paterson, Josh |e verfasserin |4 aut | |
| 700 | 1 | |a Fairbairn, Nadia |e verfasserin |4 aut | |
| 700 | 1 | |a Socías, M Eugenia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Substance use & addiction journal |d 2024 |g 45(2024), 2 vom: 23. März, Seite 176-180 |w (DE-627)NLM367447452 |x 2976-7350 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2024 |g number:2 |g day:23 |g month:03 |g pages:176-180 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/29767342231222103 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2024 |e 2 |b 23 |c 03 |h 176-180 | ||